[
THE INVESTOR]
Boryung Biopharma is to research immune cell treatments using umbilical cord blood in collaboration with Seoul St. Mary’s Hospital.
The company said on July 14, that it signed an agreement with the hospital to conduct research in a 5-year project aimed at developing a range of treatments for immune cells.
By Choi He-suk (
cheesuk@heraldcorp.com)
